Aldosterone, Salt & Blood Pressure Dysregulation: Root Causes, Mechanisms & Integrative Support

The Forgotten Hormone Behind Hypertension

When most people think about high blood pressure, they think about sodium, stress, or cardiovascular disease. Rarely do they consider aldosterone — a steroid hormone produced by the adrenal cortex that is, in many cases, the primary driver of treatment-resistant hypertension, electrolyte imbalance, and cardiovascular damage.

Aldosterone is the master regulator of sodium and potassium balance in the body. It acts on the kidneys, colon, sweat glands, and salivary glands to retain sodium (and water) while excreting potassium. When aldosterone is chronically elevated — or when its signaling is dysregulated — the consequences extend far beyond blood pressure: heart remodeling, kidney damage, inflammation, insulin resistance, and neurological dysfunction all follow.

The Renin-Angiotensin-Aldosterone System (RAAS)

Aldosterone does not act in isolation. It is the terminal effector of the renin-angiotensin-aldosterone system (RAAS) — one of the body's most powerful blood pressure and fluid regulation cascades:

1. Renin is released by the kidneys in response to low blood pressure, low sodium, or sympathetic nervous system activation
2. Renin cleaves angiotensinogen (from the liver) into angiotensin I
3. ACE (angiotensin-converting enzyme) converts angiotensin I into angiotensin II
4. Angiotensin II stimulates the adrenal cortex to release aldosterone
5. Aldosterone acts on the kidneys to retain sodium and water, raising blood volume and blood pressure

This system is designed for short-term blood pressure rescue — not chronic activation. When RAAS is persistently stimulated, or when aldosterone is produced autonomously, the result is sustained hypertension, potassium depletion, and end-organ damage.

Root Causes of Aldosterone Dysregulation

1. Primary Hyperaldosteronism (Conn's Syndrome)

The adrenal glands produce excess aldosterone autonomously, independent of RAAS stimulation. This is the most common cause of secondary hypertension — affecting an estimated 5–10% of all hypertensive patients and up to 20% of those with treatment-resistant hypertension. Causes include:

• Unilateral adrenal adenoma (Conn's adenoma) — most common; surgically curable
• Bilateral adrenal hyperplasia — both adrenal glands overproduce aldosterone; managed medically
• Adrenal carcinoma — rare
• Familial hyperaldosteronism — genetic forms (FH-I through FH-IV)

2. Secondary Hyperaldosteronism

RAAS is appropriately activated in response to a perceived volume deficit, but the underlying cause perpetuates the cycle:

• Renal artery stenosis (reduced renal perfusion triggers renin release)
• Congestive heart failure (reduced cardiac output activates RAAS)
• Cirrhosis with ascites
• Nephrotic syndrome
• Chronic dehydration or very low sodium intake

3. Chronic Stress & Cortisol Cross-Reactivity

Cortisol and aldosterone share structural similarity and both bind mineralocorticoid receptors (MRs). Under normal conditions, the enzyme 11β-HSD2 inactivates cortisol in mineralocorticoid-sensitive tissues, preventing it from activating MRs. When this enzyme is overwhelmed — by chronic cortisol excess, licorice root consumption, or genetic variants — cortisol acts like aldosterone, driving sodium retention and hypertension.

4. Insulin Resistance & Hyperinsulinemia

Insulin directly stimulates aldosterone secretion from the adrenal cortex. Hyperinsulinemia — the hallmark of insulin resistance and metabolic syndrome — chronically elevates aldosterone, creating a bidirectional relationship: aldosterone worsens insulin resistance by promoting inflammation and impairing glucose uptake, while insulin resistance drives more aldosterone production.

5. Obesity & Adipose-Derived Aldosterone Secretagogues

Visceral adipose tissue secretes factors (including oxidized lipids and complement proteins) that directly stimulate adrenal aldosterone production, independent of RAAS. This explains why obesity is strongly associated with hyperaldosteronism even in the absence of a discrete adrenal tumor.

6. Low Potassium & Magnesium

Hypokalemia stimulates aldosterone secretion, creating a vicious cycle: aldosterone depletes potassium, which further stimulates aldosterone. Magnesium deficiency impairs potassium retention at the kidney level, compounding the problem.

7. Adrenal Insufficiency & Low Aldosterone

The opposite problem — insufficient aldosterone production — occurs in primary adrenal insufficiency (Addison's disease) and can cause severe sodium wasting, hypotension, hyperkalemia, and life-threatening adrenal crisis. Salt craving, orthostatic hypotension, and fatigue are hallmark symptoms.

Clinical Consequences of Chronic Aldosterone Excess

• Hypertension — often treatment-resistant; does not respond well to standard antihypertensives
• Hypokalemia — muscle weakness, cramps, fatigue, cardiac arrhythmias
• Metabolic alkalosis — from potassium and hydrogen ion loss
• Cardiac remodeling — aldosterone directly promotes myocardial fibrosis and left ventricular hypertrophy, independent of blood pressure effects
• Kidney damage — glomerular hypertension and proteinuria; accelerated CKD progression
• Insulin resistance — aldosterone impairs insulin signaling in adipose and muscle tissue
• Inflammation — aldosterone activates NF-κB and promotes vascular inflammation and endothelial dysfunction
• Neurological effects — emerging evidence links hyperaldosteronism to anxiety, depression, and cognitive impairment via mineralocorticoid receptor activation in the brain

Diagnosis

Screening

• Plasma aldosterone-to-renin ratio (ARR) — the primary screening test; a ratio >20–30 (with aldosterone >15 ng/dL) is suspicious for primary hyperaldosteronism
• Should be tested in: treatment-resistant hypertension, hypertension + hypokalemia, hypertension + adrenal incidentaloma, hypertension onset before age 40, or family history of early hypertension/stroke

Confirmatory Testing

• Oral sodium loading test or saline infusion test — failure to suppress aldosterone confirms autonomous production
• Fludrocortisone suppression test

Localization

• CT adrenal — identifies adenoma or hyperplasia (may miss small adenomas)
• Adrenal vein sampling (AVS) — gold standard for distinguishing unilateral from bilateral disease; guides surgical vs. medical management

Additional Labs

• Serum potassium, magnesium, sodium
• 24-hour urine aldosterone and sodium
• Morning cortisol and ACTH (to rule out cortisol-driven mineralocorticoid excess)
• Fasting insulin and HOMA-IR (assess insulin-aldosterone connection)

Conventional Treatment

• Unilateral adenoma: Laparoscopic adrenalectomy — curative in ~50% of cases; improves blood pressure in nearly all
• Bilateral hyperplasia: Mineralocorticoid receptor antagonists — spironolactone (first-line) or eplerenone (more selective, fewer side effects)
• Secondary hyperaldosteronism: Treat the underlying cause (renal artery stenosis, heart failure, etc.)

Integrative & Root-Cause Protocols

Dietary Foundations

• Potassium-rich diet — avocado, leafy greens, sweet potato, banana, beans; counteracts aldosterone-driven potassium loss and blunts RAAS activation
• Magnesium-rich foods — pumpkin seeds, dark chocolate, spinach, almonds; supports potassium retention and vascular tone
• Moderate sodium — neither very low nor very high; extreme sodium restriction paradoxically activates RAAS
• Anti-inflammatory diet — reduces adipose-derived aldosterone secretagogues; emphasize omega-3s, polyphenols, and fiber
• Avoid licorice root — glycyrrhizin inhibits 11β-HSD2, causing cortisol to act as a mineralocorticoid

Key Supplements

• Magnesium glycinate (400–600mg/day) — supports potassium retention, reduces vascular resistance, and blunts RAAS activation
• Potassium (dietary first; supplement with caution) — directly counters aldosterone-driven hypokalemia
• Vitamin D3 (2,000–5,000 IU/day) — suppresses renin expression; deficiency is associated with RAAS overactivation
• CoQ10 (200–300mg/day) — reduces blood pressure and supports mitochondrial function in vascular tissue
• Berberine — improves insulin sensitivity, reducing insulin-driven aldosterone stimulation
• Omega-3 fatty acids (2–3g EPA+DHA/day) — reduce vascular inflammation and modestly lower blood pressure

Lifestyle Interventions

• Weight loss — reduces adipose-derived aldosterone secretagogues; even 5–10% body weight reduction meaningfully lowers aldosterone
• Aerobic exercise — reduces RAAS activity and improves endothelial function; aim for 150+ minutes/week
• Stress management — reduces cortisol-driven mineralocorticoid receptor activation; HRV training, breathwork, sleep optimization
• Sleep optimization — sleep apnea is a significant driver of RAAS activation; treat OSA aggressively
• Reduce alcohol — alcohol activates RAAS and impairs aldosterone metabolism

The Salt Paradox: Why Sodium Advice Is More Complex Than You Think

The relationship between salt and blood pressure is not linear. In aldosterone-driven hypertension, sodium restriction alone is insufficient — and may paradoxically worsen RAAS activation. The real target is aldosterone itself: reducing its production (through weight loss, insulin sensitization, and stress management) and blocking its receptor (through spironolactone or eplerenone) produces far greater blood pressure reduction than sodium restriction alone.

Conversely, in adrenal insufficiency with low aldosterone, sodium restriction can be dangerous — these patients need adequate salt intake to maintain blood pressure and prevent adrenal crisis.

Understanding aldosterone transforms the clinical approach to hypertension from a one-size-fits-all sodium restriction model to a precision medicine framework that identifies and corrects the hormonal root cause.

Related reading: Cushing's Syndrome & Cortisol Excess | Insulin Resistance: Root Causes, Mechanisms & Reversal | Hormones & Metabolic Health Hub